Observational Study on the Safety and Tolerability of Gadobutrol (Gadovist) Among Filipino Patients in Magnetic Resonance Imaging

NCT00905879 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2013-04-26

No results posted yet for this study

Summary

Patients will be recruited from those who will undergo contrast enhanced MRI. Safety and tolerability will be assessed.

Conditions

  • Magnetic Resonance Imaging

Interventions

DRUG

Gadobutrol (Gadovist, BAY86-4875)

Patients who will need to undergo contrast enhanced MRI with gadobutrol (Gadovist)

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Completion
2011-01-31

Countries

  • Philippines

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00905879 on ClinicalTrials.gov